Latest News and Press Releases

Baton Rouge, LA, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that a new...

Baton Rouge, LA, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today provides shareholders an...

Baton Rouge, LA, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the...

Adhera to develop MLR-1023 as a new drug for Type I diabetes with a focus on C-peptide positive patients (~320,000 – 480,000 patients in U.S.)Laboratory and clinical research support MLR-1023 as the...

Adhera to develop MLR-1019 (armesocarb) as a new class of drug for Parkinson’s Disease (PD), representing the only drug to address both movement and non-movement symptoms of PDArmesocarb is the active...

Adhera to acquire and develop MLR-1019 (armesocarb), the API in mesocarb – a drug previously sold in Europe for 37 years – for Parkinson’s DiseaseMLR-1019, a Phase 2-ready product, could have...

Baton Rouge, LA, April 23, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera Therapeutics" or the "Company"), a clinical stage biopharmaceutical company engaged in the...

RESEARCH TRIANGLE PARK, NC, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and...

RESEARCH TRIANGLE PARK, NC, July 02, 2019 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and...

RESEARCH TRIANGLE PARK, NC, April 04, 2019 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and...